Abbott Gmbh & Co. KG Alinity ci series System Control Module (SCM) recall — FDA Z-2701-2020
Quality Control results were not properly evaluated for QC failures.
Overview of recall records associated with Abbott Gmbh & Co. KG, including dates, categories and classifications where available.
Classification mix: Class II: 5.
Quality Control results were not properly evaluated for QC failures.
There is a potential to generate incorrect patient results for the following assays: Alkaline Phosphatase, Amylase, Creatine Kinase, and Gamma Glutamyl Transferase.
Abbott identified that samples tested for ARCHITECT STAT High Sensitive Troponin I and STAT High Sensitivity Troponin I assays (LN 3P25 and LN 2R98) may show interaction when processed…
An erroneous concentration value for hepatitis A virus was utilized during manufacture, leading to a decreased amount of antigen used for the impacted lots.
Abbott has identified potential performance issues for the Alinity ci -series Software version 2.6.2 and earlier.
This page summarizes recall records in which the official source identifies Abbott Gmbh & Co. KG as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.